Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study
Authors
Keywords
-
Journal
Diabetes Therapy
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-16
DOI
10.1007/s13300-021-01133-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association Between DPP-4 Inhibitors and COVID-19 Related Outcomes Among Patients With Type 2 Diabetes
- (2021) Yunha Noh et al. DIABETES CARE
- Use of dipeptidyl peptidase‐4 inhibitors and prognosis of COVID ‐19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study
- (2021) Ronan Roussel et al. DIABETES OBESITY & METABOLISM
- Clinical Characteristics and Outcomes of COVID‐19 in Patients with Type 2 Diabetes in Turkey: A Nationwide Study (TurCoviDia)
- (2021) Alper Sonmez et al. Journal of Diabetes
- Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
- (2021) B. M. Bonora et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Unexpectedly lower mortality rates in COVID-19 patients with and without type 2 diabetes in Istanbul
- (2021) Ilhan Satman et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes
- (2020) Lihua Zhu et al. Cell Metabolism
- Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication
- (2020) Yuchen Chen et al. DIABETES CARE
- Obesity Is a Risk Factor for Greater COVID-19 Severity
- (2020) Feng Gao et al. DIABETES CARE
- Exposure to DPP ‐4 inhibitors and COVID ‐19 among people with type 2 diabetes. A case–control study
- (2020) Gian Paolo Fadini et al. DIABETES OBESITY & METABOLISM
- COVID-19 and diabetes: Can DPP4 inhibition play a role?
- (2020) Gianluca Iacobellis DIABETES RESEARCH AND CLINICAL PRACTICE
- Kidney disease is associated with in-hospital death of patients with COVID-19
- (2020) Yichun Cheng et al. KIDNEY INTERNATIONAL
- Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19
- (2020) Mandeep R. Mehra et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID‐19 and comorbidities: A role for dipeptidyl peptidase 4 ( DPP4 ) in disease severity?
- (2020) Margaret F. Bassendine et al. Journal of Diabetes
- Is DPP4 inhibition a comrade or adversary in COVID-19 infection
- (2020) Rinkoo Dalan DIABETES RESEARCH AND CLINICAL PRACTICE
- Hyperglycaemia on admission to hospital and COVID-19
- (2020) Celestino Sardu et al. DIABETOLOGIA
- Diabetes Mellitus Association with Coronavirus Disease 2019 (COVID‐19) Severity and Mortality: A Pooled Analysis
- (2020) Gaurav Aggarwal et al. Journal of Diabetes
- DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
- (2020) Inés Valencia et al. Frontiers in Pharmacology
- Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study
- (2020) Sebastiano Bruno Solerte et al. DIABETES CARE
- Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy
- (2020) Marco Mirani et al. DIABETES CARE
- Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards
- (2020) Michael A. Nauck et al. DIABETES CARE
- Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study
- (2020) Luis M. Pérez-Belmonte et al. BMC Medicine
- A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
- (2020) Chia Siang Kow et al. THERAPIE
- No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19
- (2020) Jiang-Hua Zhou et al. World Journal of Clinical Cases
- Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
- (2016) C. Klemann et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
- (2014) Erin E. Mulvihill et al. ENDOCRINE REVIEWS
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody
- (2013) K. Ohnuma et al. JOURNAL OF VIROLOGY
- Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
- (2013) V. Stalin Raj et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More